Yu Mi Kang

10PUBLICATIONS
60CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsPharmacogenomicsPacific Peoples sport and physical activity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Mar 30, 2026
Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.

Nicholas A Marston, Brian A Bergmark, Thomas A Prohaska

|Feb 27, 2026
Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.

Michael A Nauck, Viktoria Punov, Yu Mi Kang

|Jun 22, 2025
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial.

Yu Mi Kang, Robert P Giugliano, Xinhui Ran

|Apr 11, 2025
Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials.

Yu Mi Kang, Viktoria Punov, Soo Lim

|Feb 20, 2025
Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight or Obesity.

Matthew M Y Lee, Nazim Ghouri, Anoop Misra

|Apr 07, 2024
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.

Siddharth M Patel, Yu Mi Kang, KyungAh Im

Pageof 2

Frequent Collaborators

3 joint publications

Michael A Nauck

3 joint publications

Marc S Sabatine

2 joint publications

Chang Hee Jung

2 joint publications

Soo Lim